New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
08:16 EDTBIIBBiogen signs Factor VIII license agreement with Amunix
Biogen Idec has exercised its option to enter into an exclusive, worldwide license agreement with Amunix Operating to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties. Amunix will receive an upfront $1M payment and will also be eligible to receive up to $38M in clinical and commercial milestone payments. In addition, royalties will be paid on commercial sales by Biogen Idec for Factor VIII products incorporating Amunix proprietary XTEN technology.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
06:54 EDTBIIBBiogen October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
October 20, 2014
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
October 14, 2014
11:23 EDTBIIBBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 7, 2014
07:24 EDTBIIBAlliance for Regenerative Medicine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use